REFERENCES
1. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976;26:1054-9.
4. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg 2000;70:327-34.
5. Onodera H. The role of the thymus in the pathogenesis of myasthenia gravis. Tohoku J Exp Med 2005;207:87-98.
6. Scheife RT, Hills JR, Munsat TL. Myasthenia gravis: signs, symptoms, diagnosis, immunology, and current therapy. Pharmacotherapy 1981;1:39-54.
7. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. myasthenia gravis study group. Neurology 1998;50:1778-83.
8. Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56:94-6.
9. Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide. Ann Neurol 2003;53:29-34.
10. Ponseti JM, Azem J, Fort JM, Codina A, Montoro JB, Armengol M. Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study. Clin Neurol Neurosurg 2005;107:187-90.
11. Chiu HC, Chen WH, Yeh JH. The six year experience of plasmapheresis in patients with myasthenia gravis. Ther Apher 2000;4:291-5.
12. Wegner B, Ahmed I. Intravenous immunoglobulin monotherapy in long-term treatment of myasthenia gravis. Clin Neurol Neurosurg 2002;105:3-8.
13. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology. Neurology 2000;55:7-15.
14. Furlund Owe J, Skulstad Davidsen E, Eide GE, Gerdts E, Gilhus NE. Left ventricular long-axis function in myasthenia gravis. J Neurol 2008;255:1777-84.
15. Ashok PP, Ahuja GK, Manchanda SC, Jalal S. Cardiac involvement in myasthenia gravis. Acta Neurol Scand 1983;68:113-20.
16. Asensio E, Gómez M, Narváez R, Castillo L, Oseguera J, Dorantes J, Orea A, Hernandez P, Rebollar V. Description of the resting electrocardiogram in a series of patients with myasthenia gravis. Rev Invest Clin 2003;55:270-5.
17. Calin C, Savu O, Dumitru D, Ghiorghiu I, Calin A, Capraru C, Popescu BA, Croitoru M, Vilciu C, Ginghina C. Cardiac involvement in myasthenia gravis - is there a specific pattern? Rom J Intern Med 2009;47:179-89.
18. Douchet MP, Quiring E, Bronner F, Vi-Fane R, Messier M, Chauvin M, Warter JM. Paradoxal lowering of parasympathetic indices in myasthenic patients. Arch Mal Coeur Vaiss 1999;92:711-7.
19. Vernino S, Cheshire WP, Lennon VA. Myasthenia gravis with autoimmune autonomic neuropathy. Auton Neurosci 2001;88:187-92.
20. de Jongste MJ, Oosterhuis HJ, Lie KI. Intractable ventricular tachycardia in a patient with giant cell myocarditis, thymoma and myasthenia gravis. Int J Cardiol 1986;13:374-8.
21. Hofstad H, Ohm OJ, Mørk SJ, Aarli JA. Heart disease in myasthenia gravis. Acta Neurol Scand 1984;70:176-84.
22. Suzuki S, Utsugisawa K, Yoshikawa H, Motomura M, Matsubara S, Yokoyama K, Nagane Y, Maruta T, Satoh T, Sato H, Kuwana M, Suzuki N. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol 2009;66:1334-8.
23. Suzuki S, Baba A, Kaida K, Utsugisawa K, Kita Y, Tsugawa J, Ogawa G, Nagane Y, Kuwana M, Suzuki N. Cardiac involvements in myasthenia gravis associated with anti-Kv1.4 antibodies. Eur J Neurol 2014;21:223-30.
24. Senda Y, Sugimura K, Koike Y, Matsuoka Y, Takahashi A. Concurrence of acute autonomic and sensory neuropathy and myasthenia gravis - a case report and pathogenetic considerations. Rinsho Shinkeigaku 1989;29:332-5.
25. Pande R, Leis AA. Myasthenia gravis, thymoma, intestinal pseudo-obstruction, and neuronal nicotinic acetylcholine receptor antibody. Muscle Nerve 1999;22:1600-2.
26. Bogousslavsky J, Regli F, Doret AM, Fulpius BW, Ostinelli B, Rabinowicz T, Ruzicka J. Encephalopathy, peripheral neuropathy, dysautonomia, myasthenia gravis, malignant thymoma, and antiacetylcholine receptor antibodies in the CSF. Eur Neurol 1983;22:301-6.
27. Anderson NE, Hutchinson DO, Nicholson GJ, Aitcheson F, Nixon JM. Intestinal pseudo-obstruction, myasthenia gravis, and thymoma. Neurology 1996;47:985-7.
28. Stoica E, Enulescu O. Deficiency of sympathetic nervous system function in myasthenia. J Auton Nerv Syst 1992;38:69-76.
29. Evoli A, Minicuci GM, Vitaliani R, Battaglia A, Della Marca G, Lauriola L, Fattorossi A. Paraneoplastic diseases associated with thymoma. J Neurol 2007;254:756-62.
30. Thorlacius S, Aarli JA, Riise T, Matre R, Johnsen HJ. Associated disorders in myasthenia gravis: autoimmune diseases and their relation to thymectomy. Acta Neurol Scand 1989;80:290-5.
31. Stein PK, Bosner MS, Kleiger RE, Conger BM. Heart rate variability: a measure of cardiac autonomic tone. Am Heart J 1994;127:1376-81.
32. Clinical competence in ambulatory electrocardiography. A statement for physicians from the ACP/ACC/AHA Task Force on Clinical Privileges in Cardiology. J Am Coll Cardiol 1993;22:331-5.
33. Vikman S, Mäkikallio TH, Yli-Mäyry S, Pikkujämsä S, Koivisto AM, Reinikainen P, Airaksinen KE, Huikuri HV. Altered complexity and correlation properties of R-R interval dynamics before the spontaneous onset of paroxysmal atrial fibrillation. Circulation 1999;100:2079-84.
34. Valkama JO, Huikuri VH, Koistinen MJ, Yli-Mäyry S, Airaksinen KE, Myerburg RJ. Relation between heart rate variability and spontaneous and induced ventricular arrhythmias in patients with coronary artery disease. J Am Coll Cardiol 1995;25:437-43.
35. Elgoyhen AB, Johnson DS, Boulter J, Vetter DE, Heinemann S. Alpha 9: an acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell 1994;79:705-15.
36. Lips KS, Pfeil U, Kummer W. Coexpression of alpha 9 and alpha 10 nicotinic acetylcholine receptors in rat dorsal root ganglion neurons. Neuroscience 2002;115:1-5.
37. Lewis SW, Ron MA, Newsom-Davis J. Absence of central functional cholinergic deficits in myasthenia gravis. J Neurol Neurosurg Psychiatry 1989;52:258-61.
38. Nóbrega AC, dos Reis AF, Moraes RS, Bastos BG, Ferlin EL, Ribeiro JP. Enhancement of heart rate variability by cholinergic stimulation with pyridostigmine in healthy subjects. Clin Auton Res 2001;11:11-7.
39. Behling A, Moraes RS, Rohde LE, Ferlin EL, Nóbrega AC, Ribeiro JP. Cholinergic stimulation with pyridostigmine reduces ventricular arrhythmia and enhances heart rate variability in heart failure. Am Heart J 2003;146:494-500.
41. Hamed SA. Comorbid nervous system manifestations and disorders with myasthenia gravis: Evidences and possible mechanisms. J Neurol Neurosci 2012;3:2.
